Clinical trials · New York, NY
Prostate Cancer Recurrent clinical trials in New York
We’re tracking 34 recruiting prostate cancer recurrent studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06952803RecruitingPhase 3
Testing a new drug for men with BRCA-related prostate cancer
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
New York, New YorkAges 18 years+ - NCT05997017RecruitingPhase 2
Nab-sirolimus plus letrozole for advanced endometrial cancer
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
New York, New YorkAges 18 years+ - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
New York, New YorkAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new drug to standard care for prostate cancer
This trial tests a new study drug (AAA817) against the usual treatments for men with a certain type of advanced prostate cancer that has spread and is no longer responding to a targeted radiation therapy (177Lu-PSMA). The goal is to see if the new drug can help control the disease longer.
The Bronx, New YorkAges 18–100 - NCT05593497RecruitingPhase 2
Study of hormone therapy plus capivasertib before prostate surgery
This Phase 2 trial tests whether adding capivasertib to intensified hormone therapy (leuprolide plus abiraterone) given before prostate surgery can improve outcomes for men with high-risk localized prostate cancer that has a specific tumor marker (PTEN loss). You would also have extra blood tests, scans, and a tissue biopsy for tumor testing.
The Bronx, New YorkAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Lake Success, New YorkAges 18 years+ - NCT04729114RecruitingPhase 1
Safety and dose test of PRL-02 shot for advanced prostate cancer
This Phase 1 study tests how safe PRL-02 depot (an injection) is and finds the best dose for men with advanced prostate cancer. It may help determine a new treatment option for cancers that have spread or are getting worse despite standard care.
Morristown, New JerseyAges 18 years+ - NCT06990880RecruitingPhase 1/Phase 2
Study of GSK5458514 alone or with other drugs for prostate cancer
This trial tests a new drug, GSK5458514, either alone or with other cancer treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if the drug can slow down the cancer.
East Brunswick, New JerseyAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
East Brunswick, New JerseyAges 18 years+ - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Commack, New YorkAges 18 years+
Hear when a new Prostate Cancer Recurrent trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Prostate Cancer Recurrent trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting prostate cancer recurrent studies listed above.
- Memorial Sloan Kettering Cancer Center · 2 studies
- Research Site · 2 studies
- Garden State Urology
- GSK Investigational Site
- James J. Peters VA Medical Center
- Memorial Sloan Kettering Basking Ridge
- Memorial Sloan Kettering Bergen
- Memorial Sloan Kettering Commack
What taking part in a prostate cancer recurrent study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting prostate cancer recurrent studies in New York.
Common questions
- Are there prostate cancer recurrent clinical trials near New York?
- Yes. We're currently tracking 34 recruiting prostate cancer recurrent studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer recurrent study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer recurrent studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.